Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of Kohjin Bio Co., Ltd.. A complete text table follows the diagram.
Cell processing adds a meaningful third stream, giving the biotech supplier a balanced three-business mix.
Swipe to explore
Every category amount is a reported EDINET XBRL fact. Nodes described as arithmetic bridges are calculated residuals and do not imply a separately reported filing line.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| Tissue culture business | 1 | 1.3B | 51.2% of reported total |
| Microbiological business | 1 | 686M | 27.4% of reported total |
| Cell process business | 1 | 536M | 21.4% of reported total |
| Other & rounding | 1 | 0 | 0.0% of reported total |
| Revenues From External Customers | 2 | 2.5B | Reported six-month total · ¥2.5B |
| Operating profit | 3 | 258M | 10.3% operating margin |
| Operating costs & expenses | 3 | 2.2B | Arithmetic residual to reported operating profit |
| Profit before tax | 4 | 274M | Reported pretax result |
| Kohjin Bio's tissue-culture business is the largest engine | 3 | 16M | Tissue culture generated ¥1.282bn of external revenue, followed by microbiological business at ¥686m. |
| Net profit attributable to owners | 5 | 202M | Reported parent-company result |
| Tax, attribution & other | 5 | 71.6M | Arithmetic bridge to owners' profit |
| From | To | Value |
|---|---|---|
| Tissue culture business | Revenues From External Customers | 1.3B |
| Microbiological business | Revenues From External Customers | 686M |
| Cell process business | Revenues From External Customers | 536M |
| Other & rounding | Revenues From External Customers | 0 |
| Revenues From External Customers | Operating profit | 258M |
| Revenues From External Customers | Operating costs & expenses | 2.2B |
| Operating profit | Profit before tax | 258M |
| Kohjin Bio's tissue-culture business is the largest engine | Profit before tax | 16M |
| Profit before tax | Net profit attributable to owners | 202M |
| Profit before tax | Tax, attribution & other | 71.6M |